4.6 Article

DELAYED NEUTRALIZATION OF INTERLEUKIN 6 REDUCES ORGAN INJURY, SELECTIVELY SUPPRESSES INFLAMMATORY MEDIATOR, AND PARTIALLY NORMALIZES IMMUNE DYSFUNCTION FOLLOWING TRAUMA AND HEMORRHAGIC SHOCK

期刊

SHOCK
卷 42, 期 3, 页码 218-227

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SHK.0000000000000211

关键词

MCP-1; KC; IP10

资金

  1. NIH/NIGMS [P50GM053789]

向作者/读者索取更多资源

An excessive and uncontrolled systemic inflammatory response is associated with organ failure, immunodepression, and increased susceptibility to nosocomial infection following trauma. Interleukin 6 ( IL-6) plays a particularly prominent role in the host immune response after trauma with hemorrhage. However, as a result of its pleiotropic functions, the effect of IL-6 in trauma and hemorrhage is still controversial. It remains unclear whether suppression of IL-6 after hemorrhagic shock and trauma will attenuate organ injury and immunosuppression. In this study, C57BL/6 mice were treated with anti-mouse IL-6 monoclonal antibody immediately prior to resuscitation in an experimental model combining hemorrhagic shock and lower-extremity injury. Interleukin 6 levels and signaling were transiently suppressed following administrations of anti-IL-6 monoclonal antibody following hemorrhagic shock and lower-extremity injury. This resulted in reduced lung and liver injury, as well as suppression in the levels of key inflammatory mediators including IL-10, keratinocyte-derived chemokine, monocyte chemoattractant protein 1, and macrophage inhibitory protein 1 alpha at both 6 and 24 h. Furthermore, the shift to T(H)2 cytokine production and suppressed lymphocyte response were partly prevented. These results demonstrate that IL-6 is not only a biomarker but also an important driver of injury-induced inflammation and immune suppression in mice. Rapid measurement of IL-6 levels in the early phase of postinjury care could be used to guide IL-6-based interventions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据